The funds involved pursue the goal of concluding discount agreements with all suitable pharmaceutical companies pursuant to § 130a Abs. 8 SGB V for the active ingredient tocilizumab. The contract is concluded within the framework of the open-house biologics procedure of the participating funds:

Individual negotiations on the content of the contract are not conducted, uniform conditions apply. The insurance companies involved do not guarantee exclusivity to individual contractual partners. The contract period is a maximum of 24 months, starting from 01.11.2023. The contract ends no later than 31.10.2025, regardless of the date of conclusion of the contract.

All further information can be found in the participation and contract documents.

It is possible to join this open house biological process at any time within the contract period.

A contract is concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration for approval and for the company) and who confirm this in electronic form in accordance with § 126a BGB.

This notice does not concern the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust procurement law. In order to provide the widest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The procedural designation "Open Procedure" according to Section IV.1.1) used in the context of the present publication text and the indication of the award criteria in accordance with Section II.2.5) are due to the requirements of the notice form and

have no further meaning. This and the use of the medium “TED” does not imply any submission to public procurement regulations, the validity of which is not obligatory by law or procurement regulations.